Allaire J, Couture P, Leclerc M, et al. Randomized, crossover, head-to-head comparison of EPA and DHA supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA Study. Am J Clin Nutr 2016; doi: 10.3945/ajcn.116.131896.
Arnardottir HH, Dalli J, Colas RA, et al. Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol 2014;193:4235-4244.
Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83(Suppl):1505S-1519S.
Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr 2012;142:592S-599S.
Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010;106(10):1559-1569.
Claria J, Dalli J, Yacoubian S, et al. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 2012;189(5):2597-2607.
Corder KE, Newsham KR, McDaniel JL, et al. Effects of short-term docosahexaenoic acid supplementation on markers of inflammation after eccentric strength exercise in women. J Sports Sci Med 2016;15:176-183.
Dangi B, Obeng M, Nauroth JM, et al. Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J Biol Chem 2009;284(22):14744-14759.
Delfan M, Ebrahim K, Baesi F, et al. The immunomodulatory effects of fish-oil supplementation in elite paddlers: a pilot randomized double blind placebo-controlled trial. Prostaglandins Leukot Essent Fatty Acids 2015;99:35-40.
Endo J, Sano M, Isobe Y, et al. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med 2014;211(8):1673-1687.
Espersen GT, Grunnet N, Lervang HH, et al. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. Clin Rheumatol 1992;11(3):393-395.
Ferguson JF, Mulvey CK, Patel PN, et al. Omega-3 polyunsaturated fatty acid supplementation and the response to evoked endotoxemia in healthy volunteers. Mol Nutr Food Res 2014;58(3):601-613.
Gonzalez-Periz A, Horrillo R, Ferre N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23(6):1946-1957.
González-Périz A, Planagumà A, Gronert K, et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 2006;20(14):2537-2539.
Han JM, Patterson SJ, Speck M, et al. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. J Immunol 2014;192:623-629.
Hirakata T, Lee HC, Ohba M, et al. Dietary ω-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. FASEB J 2019;33(3):3392-3403.
Hong S, Gronert K, Devchand PR, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278(17):14677-14687.
Hughes DA, Pinder AC, Piper Z, et al. Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. Am J Clin Nutr 1996;63(2):267-272.
Isobe Y, Arita M, Matsueda S. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 2012;287(13):10525-10534.
Itariu BK, Zeyda M, Hochbrugger EE, et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am J Clin Nutr 2012;96:1137-1149.
James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71(1 Suppl):343S-348S.
Jaudszus A, Gruen M, Watzl B, et al. Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells. J Lipid Res 2013;54:923-935.
Jouris KB, McDaniel JL, Weiss EP. The effect of omega-3 fatty acid supplementation on the inflammatory response to eccentric strength exercise. J Sports Sci Med 2011;10:432-438.
Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun 2012;26(6):988-995.
Kolahi S, Ghorbanihaghjo A, Alizadeh S, et al. Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. Clin Biochem 2010;43(6):576-580.
Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990;33(6):810-820.
Kromhout D, de Goede J. Update on cardiometabolic health effects of ω-3 fatty acids. Curr Opin Lipidol 2014;25(1):85-90.
Larsson SC, Kumlin M, Ingelman-Sundberg M, et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79(6):935-945.
Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985;312(19):1217-1224.
Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 2012;58(10):1476-1484.
McDaniel JC, Massey K, Nicolaou A. Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds. Wound Repair Regen 2011;19(2):189-200.
McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity 2014;41:36-48.
Merched AJ, Ko K, Gotlinger KH, et al. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008;22:3595-3606.
Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 2012;142(3):614S-625S.
Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58(20):2047-2067.
Neuhofer A, Zeyda M, Mascher D, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 2013;62:1945-1956.
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 2007;447(7178):1116-1120.
Oh SF, Vickery TW, Serhan CN. Chiral lipidomics of E-series resolvins: aspirin and the biosynthesis of novel mediators. Biochim Biophys Acta 2011;1811(11):737-747.
Oliver E, McGillicuddy F, Phillips C, et al. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. Proc Nutr Soc 2010;69:232-243.
Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003;108(2):155-160.
Rees D, Miles EA, Banerjee T, et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 2006;83(2):331-342.
Russell FD, Bürgin-Maunder CS. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs 2012;10(11):2535-2559.
Satoh-Asahara N, Shimatsu A, Sasaki Y, et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012;35:2631-2639.
Schmidt EB, Pedersen JO, Varming K, et al. N-3 fatty acids and leukocyte chemotaxis. Effects in hyperlipidemia and dose-response studies in healthy men. Arterioscler Thromb 1991;11(2):429-435.
Schuchardt JP, Ostermann AI, Stork L, et al. Effect of DHA supplementation on oxylipin levels in plasma and immune cell stimulated blood. Prostaglandins Leukot Essent Fatty Acids 2017;121:76-87.
Spencer M, Finlin BS, Unal R, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes 2013;62:1709-1717.
Thesing CS, Bot M, Milaneschi Y, et al. Omega-3 polyunsaturated fatty acid levels and dysregulations in biological stress systems. Psychoneuroendocrinology 2018;97:206-215.
Titos E, Clària J. Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. Prostaglandins Other Lipid Mediat 2013;107:77-84.
Titos E, Rius B, Gonzalez-Periz A, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011;187(10):5408-5418.
Vik A, Dalli J, Hansen TV. Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid. Bioorg Med Chem Lett 2017;27(11):2259-2266.
Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12):1796-1808.
Weitz D, Weintraub H, Fisher E, et al. Fish oil for the treatment of cardiovascular disease. Cardiol Rev 2010;18(5):258-263.
Yamada H, Oshiro E, Kikuchi S, et al. Hydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs. J Lipid Res 2014;55(5): 895–904.
Yang R, Chiang N, Oh SF, et al. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol 2011;Chapter 14:Unit 14.26.